GLP-1 goliath updates demand for top weight loss drug
Novo Nordisk reported Q3 2025 earnings on November 5, showing continued strong demand for its weight-loss drug Wegovy, despite rising costs and pricing
(TheStreet, 2025-11-05T21:24:41Z)